Denali Therapeutics Inc (NASDAQ: DNLI) is -2.14% lower on its value in year-to-date trading and has touched a low of $15.45 and a high of $33.31 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DNLI stock was last observed hovering at around $21.29 in the last trading session, with the day’s loss setting it -0.29%.
Currently trading at $21.00, the stock is 4.19% and 13.75% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.17 million and changing -1.36% at the moment leaves the stock -5.67% off its SMA200. DNLI registered -9.72% loss for a year compared to 6-month loss of -5.49%. The firm has a 50-day simple moving average (SMA 50) of $5.86 and a 200-day simple moving average (SMA200) of -$10.76.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 27.04% gain in the last 1 month and extending the period to 3 months gives it a -7.28%, and is 6.33% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.32% over the week and 6.23% over the month.
Denali Therapeutics Inc (DNLI) has around 445 employees, a market worth around $2.92B and $330.53M in sales. Profit margin for the company is -43.94%. Distance from 52-week low is 35.92% and -36.96% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.50%).
Denali Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.71 with sales reaching $14.15M over the same period.The EPS is expected to shrink by -150.41% this year, but quarterly earnings will post -80.40% year-over-year. Quarterly sales are estimated to shrink -59.70% in year-over-year returns.
312 institutions hold shares in Denali Therapeutics Inc (DNLI), with institutional investors hold 92.26% of the company’s shares. The shares outstanding are 138.39M, and float is at 111.97M with Short Float at 7.92%. Institutions hold 79.48% of the Float.
The top institutional shareholder in the company is Baillie Gifford and Company with over 14.26 million shares valued at $299.48 million. The investor’s holdings represent 10.25% of the DNLI Shares outstanding. As of Dec 30, 2023, the second largest holder is Blackrock Inc. with 11.54 million shares valued at $242.41 million to account for 8.30% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 10.83 million shares representing 7.79% and valued at over $227.52 million, while Wellington Management Group, LLP holds 5.23% of the shares totaling 7.27 million with a market value of $152.77 million.
Denali Therapeutics Inc (DNLI) Insider Activity
The most recent transaction is an insider sale by SATO VICKI L, the company’s Director. SEC filings show that SATO VICKI L sold 1,666 shares of the company’s common stock on Mar 15 ’24 at a price of $20.10 per share for a total of $33487.0. Following the sale, the insider now owns 0.12 million shares.
Denali Therapeutics Inc disclosed in a document filed with the SEC on Feb 15 ’24 that SATO VICKI L (Director) sold a total of 1,666 shares of the company’s common stock. The trade occurred on Feb 15 ’24 and was made at $18.37 per share for $30604.0. Following the transaction, the insider now directly holds 0.12 million shares of the DNLI stock.
Still, SEC filings show that on Feb 14 ’24, Schuth Alexander O. (COFO and Secretary) disposed off 20,128 shares at an average price of $17.66 for $0.36 million. The insider now directly holds 187,341 shares of Denali Therapeutics Inc (DNLI).
